The Impact of Physical Activity on Depression Treatment: A Literature Review
DOI:
https://doi.org/10.12775/QS.2024.16.52858Keywords
Depression, Exercise, Physical activityAbstract
Introduction
Engaging in physical exercise can have a significant impact on the treatment of mild-to-moderate mental health conditions, including depression. Existing antidepressant medications have limited clinical effectiveness as they fail to achieve a complete response in around 30% of depressed patients and do not induce remission in these individuals. Physical exercise can enhance the effects of antidepressant therapy in individuals with depression by boosting the health of neurons and improving the responsiveness to medication.
Aim of the study
The aim of the study is to investigate the role of physical activity in in the management of mental health diseases, especially depression.
Materials and methods
This study represents the current state of knowledge about the antidepressant effects of physical activity, particularly in the context of depressive disorders. It presents a comprehensive overview of how regular exercise can serve as an effective therapeutic strategy for managing depressive symptoms. PubMed and Google Scholar database was searched for articles written in English. The search included the keywords.
Results
Regular exercise significantly alleviates depressive symptoms through various mechanisms. Exercise enhances the production of endorphins, which improve mood and reduce anxiety. It also influences neurotransmitter systems, including serotonin, dopamine, and norepinephrine, which are crucial in regulating mood and emotion. Additionally, physical activity stimulates the production of brain-derived neurotrophic factor (BDNF) and transforming growth factor-beta 1 (TGF-β1), both of which support neurogenesis and synaptic plasticity, contributing to improved cognitive function and mood stabilization.
References
Katon WayneJ (2011) Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 13:7
Depression. https://www.who.int/health-topics/depression#tab=tab_1. Accessed 13 Jun 2024
Chand SP, Arif H (2023) Depression. StatPearls
Harmer B, Lee S, Rizvi A, Saadabadi A (2024) Suicidal Ideation. Acute Medicine: A Symptom-Based Approach 415–420
ICD-11 for Mortality and Morbidity Statistics. https://icd.who.int/browse/2024-01/mms/en. Accessed 13 Jun 2024
Depressive disorder (depression). https://www.who.int/news-room/fact-sheets/detail/depression. Accessed 13 Jun 2024
WALY Report | Happiness Resarch Institute. https://www.happinessresearchinstitute.com/waly-report. Accessed 13 Jun 2024
Rugulies R (2002) Depression as a predictor for coronary heart disease: A review and meta-analysis. Am J Prev Med 23:51–61
Jacobson NC, Newman MG (2017) Anxiety and depression as bidirectional risk factors for one another: A meta-analysis of longitudinal studies. Psychol Bull 143:1155–1200
Pinquart M, Duberstein PR (2010) Depression and cancer mortality: a meta-analysis. Psychol Med 40:1797–1810
Cuijpers P, Quero S, Noma H, Ciharova M, Miguel C, Karyotaki E, Cipriani A, Cristea IA, Furukawa TA (2021) Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry 20:283–293
Strawbridge R, Carter B, Marwood L, et al (2019) Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. The British Journal of Psychiatry 214:42–51
Hamon M, Blier P (2013) Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry 45:54–63
Lopez-Munoz F, Alamo C (2009) Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 15:1563–1586
Caraci F, Calabrese F, Molteni R, et al (2018) International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. Pharmacol Rev 70:475–504
Caraci F, Spampinato SF, Morgese MG, et al (2018) Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target. Pharmacol Res 130:374–384
Hamon M, Blier P (2013) Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry 45:54–63
Hirschfeld RMA (2000) History and Evolution of the Monoamine Hypothesis of Depression. J Clin Psychiatry 61:8272
Zhang FF, Peng W, Sweeney JA, Jia ZY, Gong QY (2018) Brain structure alterations in depression: Psychoradiological evidence. CNS Neurosci Ther 24:994–1003
Campbell S, MacQueen G (2004) The role of the hippocampus in the pathophysiology of major depression. Journal of Psychiatry and Neuroscience 29:417
Geerlings MI, Gerritsen L (2017) Late-Life Depression, Hippocampal Volumes, and Hypothalamic-Pituitary-Adrenal Axis Regulation: A Systematic Review and Meta-analysis. Biol Psychiatry 82:339–350
Schmaal L, Veltman DJ, Van Erp TGM, et al (2016) Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry 21:806–812
Sexton CE, MacKay CE, Ebmeier KP (2013) A systematic review and meta-analysis of magnetic resonance imaging studies in late-life depression. Am J Geriatr Psychiatry 21:184–195
Fichna J, Janecka A, Costentin J, Do Rego JC (2007) The endomorphin system and its evolving neurophysiological role. Pharmacol Rev 59:88–123
Navinés R, Martín-Santos R, Gómez-Gil E, Martínez de Osaba MJ, Gastó C (2008) Interaction between serotonin 5-HT1A receptors and beta-endorphins modulates antidepressant response. Prog Neuropsychopharmacol Biol Psychiatry 32:1804–1809
Grisel JE, Bartels JL, Allen SA, Turgeon VL (2008) Influence of β-Endorphin on anxious behavior in mice: Interaction with EtOH. Psychopharmacology (Berl) 200:105–115
Boecker H, Sprenger T, Spilker ME, Henriksen G, Koppenhoefer M, Wagner KJ, Valet M, Berthele A, Tolle TR (2008) The runner’s high: opioidergic mechanisms in the human brain. Cereb Cortex 18:2523–2531
Jaggar M, Fanibunda SE, Ghosh S, Duman RS, Vaidya VA (2019) The Neurotrophic Hypothesis of Depression Revisited: New Insights and Therapeutic Implications. Neurobiology of Depression: Road to Novel Therapeutics 43–62
Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33:88–109
Czéh B, Lucassen PJ (2007) What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? Eur Arch Psychiatry Clin Neurosci 257:250–260
De Kloet ER, Joëls M, Holsboer F (2005) Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6:463–475
Yu S, Holsboer F, Almeida OFX (2008) Neuronal actions of glucocorticoids: focus on depression. J Steroid Biochem Mol Biol 108:300–309
Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894–902
Maes M, Nowak G, Caso JR, et al (2016) Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. Mol Neurobiol 53:2927–2935
Caraci F, Copani A, Nicoletti F, Drago F (2010) Depression and Alzheimer’s disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 626:64–71
Racagni G, Popoli M (2010) The pharmacological properties of antidepressants. Int Clin Psychopharmacol 25:117–131
Zhang K, Yang C, Chang L, et al (2020) Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. Transl Psychiatry. https://doi.org/10.1038/S41398-020-0733-X
Murri MB, Ekkekakis P, Menchetti M, et al (2018) Physical exercise for late-life depression: Effects on symptom dimensions and time course. J Affect Disord 230:65–70
Gomes da Silva S, Arida RM (2015) Physical activity and brain development. Expert Rev Neurother 15:1041–1051
Walsh JJ, Tschakovsky ME (2018) Exercise and circulating BDNF: Mechanisms of release and implications for the design of exercise interventions. Appl Physiol Nutr Metab 43:1095–1104
Nabkasorn C, Miyai N, Sootmongkol A, Junprasert S, Yamamoto H, Arita M, Miyashita K (2006) Effects of physical exercise on depression, neuroendocrine stress hormones and physiological fitness in adolescent females with depressive symptoms. Eur J Public Health 16:179–184
Pedersen BK (2019) Physical activity and muscle-brain crosstalk. Nat Rev Endocrinol 15:383–392
Heinemeier K, Langberg H, Kjaer M (2003) Exercise-induced changes in circulating levels of transforming growth factor-beta-1 in humans: methodological considerations. Eur J Appl Physiol 90:171–177
Albert U, Brugnoli R, Caraci F, Dellosso B, Di Sciascio G, Tortorella A, Vampini C, Cataldo N, Pegoraro V (2016) Italian psychiatrists’ perception on cognitive symptoms in major depressive disorder. Int J Psychiatry Clin Pract 20:2–9
Martinsen EW, Hoffart A, Solberg Ø (1989) Comparing aerobic with nonaerobic forms of exercise in the treatment of clinical depression: A randomized trial. Compr Psychiatry 30:324–331
Thirlaway K, Benton D (1992) Participation in physical activity and cardiovascular fitness have different effects on mental health and mood. J Psychosom Res 36:657–665
Doyne EJ, Ossip-Klein DJ, Bowman ED, Osborn KM, McDougall-Wilson IB, Neimeyer RA (1987) Running Versus Weight Lifting in the Treatment of Depression. J Consult Clin Psychol 55:748–754
Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl HW, Blair SN (1999) Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA 281:327–334
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Daria Sieniawska, Julia Sieniawska, Patrycja Proszowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 276
Number of citations: 0
